  To generate drug molecules of desired properties with computational methods
is the holy grail in pharmaceutical research. Here we describe an AI strategy,
retro drug design, or RDD, to generate novel small molecule drugs from scratch
to meet predefined requirements, including but not limited to biological
activity against a drug target, and optimal range of physicochemical and ADMET
properties. Traditional predictive models were first trained over experimental
data for the target properties, using an atom typing based molecular descriptor
system, ATP. Monte Carlo sampling algorithm was then utilized to find the
solutions in the ATP space defined by the target properties, and the deep
learning model of Seq2Seq was employed to decode molecular structures from the
solutions. To test feasibility of the algorithm, we challenged RDD to generate
novel drugs that can activate {\mu} opioid receptor (MOR) and penetrate blood
brain barrier (BBB). Starting from vectors of random numbers, RDD generated
180,000 chemical structures, of which 78% were chemically valid. About 42,000
(31%) of the valid structures fell into the property space defined by MOR
activity and BBB permeability. Out of the 42,000 structures, only 267 chemicals
were commercially available, indicating a high extent of novelty of the
AI-generated compounds. We purchased and assayed 96 compounds, and 25 of which
were found to be MOR agonists. These compounds also have excellent BBB scores.
The results presented in this paper illustrate that RDD has potential to
revolutionize the current drug discovery process and create novel structures
with multiple desired properties, including biological functions and ADMET
properties. Availability of an AI-enabled fast track in drug discovery is
essential to cope with emergent public health threat, such as pandemic of
COVID-19.
